CINECA IRIS Institutional Research Information System

PASSIGLIA, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.970
EU - Europa 1.616
AS - Asia 1.215
SA - Sud America 56
AF - Africa 17
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.886
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.929
IT - Italia 592
SG - Singapore 409
CN - Cina 394
IE - Irlanda 338
SE - Svezia 174
VN - Vietnam 97
DE - Germania 88
GB - Regno Unito 72
FR - Francia 70
UA - Ucraina 58
HK - Hong Kong 56
IN - India 56
ID - Indonesia 51
BR - Brasile 44
KR - Corea 38
NL - Olanda 34
PL - Polonia 32
JP - Giappone 31
FI - Finlandia 29
CA - Canada 26
ES - Italia 21
AT - Austria 20
TW - Taiwan 13
JO - Giordania 12
MX - Messico 11
TR - Turchia 11
BE - Belgio 9
CH - Svizzera 9
DK - Danimarca 9
AU - Australia 8
HR - Croazia 8
MY - Malesia 8
PK - Pakistan 8
RU - Federazione Russa 8
BA - Bosnia-Erzegovina 6
GR - Grecia 6
RO - Romania 6
EG - Egitto 5
IR - Iran 5
PE - Perù 5
PT - Portogallo 5
CL - Cile 4
NG - Nigeria 4
RS - Serbia 4
SI - Slovenia 4
TG - Togo 4
TH - Thailandia 4
UZ - Uzbekistan 4
LT - Lituania 3
PS - Palestinian Territory 3
SA - Arabia Saudita 3
AP - ???statistics.table.value.countryCode.AP??? 2
AR - Argentina 2
CZ - Repubblica Ceca 2
GE - Georgia 2
IL - Israele 2
LV - Lettonia 2
ME - Montenegro 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
CO - Colombia 1
CR - Costa Rica 1
DJ - Gibuti 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
IQ - Iraq 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
MA - Marocco 1
MC - Monaco 1
NP - Nepal 1
PA - Panama 1
ZA - Sudafrica 1
Totale 5.886
Salva come PNG Salva come JPEG
Città #
Santa Clara 354
Dublin 336
Chandler 298
Singapore 298
Fairfield 261
Turin 177
Beijing 139
Ashburn 123
Houston 119
Nyköping 118
Wilmington 111
Seattle 108
Columbus 106
Medford 104
Woodbridge 98
Princeton 86
Torino 85
Cambridge 73
Dong Ket 71
Jakarta 47
Jacksonville 45
Hangzhou 39
Ann Arbor 35
Pisa 34
Milan 30
Nuremberg 28
Warsaw 27
Dearborn 24
Guangzhou 24
Seoul 23
Helsinki 21
Munich 21
Amsterdam 19
San Diego 19
Hebei 18
Nanjing 18
Central 17
Central District 17
New York 17
Los Angeles 16
Shanghai 16
Rome 15
Silver Spring 15
Norwalk 13
Paris 13
Amman 12
London 12
Tokyo 12
Chengdu 11
Hong Kong 11
Piemonte 11
Redwood City 11
Mumbai 10
Brussels 9
Stockholm 9
Vienna 9
Boston 8
Hefei 8
Toronto 7
Banja Luka 6
Genoa 6
Karachi 6
Kunming 6
Preveza 6
San Mateo 6
Chaponost 5
Chongqing 5
Fuzhou 5
Guiyang 5
Lappeenranta 5
Madrid 5
Manchester 5
Naples 5
New Delhi 5
Padova 5
Taichung 5
Upper Marlboro 5
Washington 5
Zagreb 5
Abuja 4
Asti 4
Belgrade 4
Brookline 4
Castellaneta 4
Chennai 4
Ciudad Lopez Mateos 4
Duncan 4
Falls Church 4
Frankfurt am Main 4
Hyderabad 4
Kuala Lumpur 4
Lomé 4
Mexico City 4
Newcastle upon Tyne 4
Pittsburgh 4
Preston 4
Redmond 4
San Francisco 4
Santiago 4
São Paulo 4
Totale 4.006
Salva come PNG Salva come JPEG
Nome #
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 285
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma 248
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 123
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 116
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 115
SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit 107
Improving lung cancer outcomes through smoking cessation: The women against lung cancer in Europe (WALCE) experience 106
Multisciplinary management of patients with liver metastasis from colorectal cancer 101
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 98
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 94
Clinical and molecular features of epidermal growth factor receptor (Egfr) mutation positive non‐small‐cell lung cancer (nsclc) patients treated with tyrosine kinase inhibitors (tkis): Predictive and prognostic role of co‐mutations 94
Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway 93
Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave 93
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation 93
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 91
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM) 89
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era 88
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design 87
Nintedanib in NSCLC: Evidence to date and place in therapy 86
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon? 85
Erratum to: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis (Scientific Reports, (2018), 8, 1, (13379), 10.1038/s41598-018-30780-4) 84
Circulating programmed death ligand-1 (cPD-L1) in non-small- cell lung cancer (NSCLC) 83
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 83
Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure? 82
Dealing with NSCLC EGFR mutation testing and treatment: a comprehensive review with an Italian real-world perspective 82
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 80
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib 79
Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 Waves 75
Repositioning PARP inhibitors in the treatment of thoracic malignancies 75
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?-a literature review 72
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy 70
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 68
Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer 66
Lung Cancer in Italy 64
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon 64
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 63
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 61
Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found… 60
Autocrine 17-β-estradiol/estrogen receptor-α loop determines the response to immune-checkpoint inhibitors in non-small cell lung cancer 59
Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle? 57
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer 57
Exploring the immune-checkpoint inhibitors' efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: Focus on steroids and autoimmune disease 57
COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery 57
KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges 55
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations 52
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 52
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 51
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations 50
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 49
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients 49
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 47
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 47
Real-world retrospective study of KRAS mutations in advanced nonsmall cell lung cancer in the era of immunotherapy 46
Cancer and the microbiome: Potential applications as new tumor biomarker 46
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 44
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 44
Metabolic tumor volume assessed by 18F FDG - PET CT scan as a predictive biomarker for immune checkpoint blockers in advanced NSCLC and its biological correlates 42
First-line immune-chemotherapy combination: the right strategy to fight squamous non-small-cell lung cancer?. 42
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 41
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 41
Adding chemotherapy to TKI: Can we improve first-line treatment for EGFR-mutated NSCLC patients? 38
Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment 37
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review 36
Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going? 36
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials 35
The evolving paradigm of precision medicine in lung cancer 34
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial 33
Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic Strategies 33
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations 33
Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review 32
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program 32
Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All? 32
The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences 32
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 31
Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review 31
Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients-An Italian Single-Center Experience 31
Winds From the ORIENT: New Data to Inform RATIONAL Choice? 31
Deciphering Lung Adenocarcinoma Heterogeneity: An Overview of Pathological and Clinical Features of Rare Subtypes 30
The role of germline mutations in thoracic malignancies: between myth and reality 30
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 30
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC 30
Entrectinib: A potent new TRK, ROS1, and ALK inhibitor 30
A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib 28
Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib? 28
Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression 28
The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database 26
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 26
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial 25
The role of targeted therapy for gastrointestinal tumors 25
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 24
EGFR inhibition in NSCLC: New findings…. and opened questions? 24
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 24
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun 23
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection 23
HER2-Altered Non-Small Cell Lung Cancer: A Journey from Current Approaches to Emerging Strategies 22
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer 22
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 22
RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion 21
Ramucirumab and its use in gastric cancer treatment 21
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 21
Totale 5.838
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.787
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.787
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020274 0 0 0 0 0 0 0 0 79 81 79 35
2020/2021835 24 46 102 34 79 77 34 59 79 95 50 156
2021/2022957 68 48 50 43 59 39 79 57 42 63 240 169
2022/20231.373 111 115 32 95 101 369 130 89 161 39 81 50
2023/2024751 96 136 35 69 31 47 32 40 13 78 67 107
2024/20251.426 26 134 95 221 537 167 93 107 46 0 0 0
Totale 6.094